336 related articles for article (PubMed ID: 33158816)
21. Ubiquitination of GRK2 Is Required for the β-Arrestin-Biased Signaling Pathway of Dopamine D2 Receptors to Activate ERK Kinases.
Liu H; Ma H; Zeng X; Wu C; Acharya S; Sudan SK; Zhang X
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373182
[TBL] [Abstract][Full Text] [Related]
22. Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition.
Soni UK; Wang Y; Pandey RN; Roberts R; Pressey JG; Hegde RS
Clin Cancer Res; 2023 Jan; 29(2):458-471. PubMed ID: 36394520
[TBL] [Abstract][Full Text] [Related]
23. miR-130b directly targets ARHGAP1 to drive activation of a metastatic CDC42-PAK1-AP1 positive feedback loop in Ewing sarcoma.
Satterfield L; Shuck R; Kurenbekova L; Allen-Rhoades W; Edwards D; Huang S; Rajapakshe K; Coarfa C; Donehower LA; Yustein JT
Int J Cancer; 2017 Nov; 141(10):2062-2075. PubMed ID: 28748534
[TBL] [Abstract][Full Text] [Related]
24. Insulin-like growth factor-1 receptor (IGF1R) as a novel target in chronic lymphocytic leukemia.
Yaktapour N; Übelhart R; Schüler J; Aumann K; Dierks C; Burger M; Pfeifer D; Jumaa H; Veelken H; Brummer T; Zirlik K
Blood; 2013 Aug; 122(9):1621-33. PubMed ID: 23863897
[TBL] [Abstract][Full Text] [Related]
25. Epitope-specific mechanisms of IGF1R inhibition by ganitumab.
Calzone FJ; Cajulis E; Chung YA; Tsai MM; Mitchell P; Lu J; Chen C; Sun J; Radinsky R; Kendall R; Beltran PJ
PLoS One; 2013; 8(2):e55135. PubMed ID: 23383308
[TBL] [Abstract][Full Text] [Related]
26. Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures.
Subbiah V; Naing A; Brown RE; Chen H; Doyle L; LoRusso P; Benjamin R; Anderson P; Kurzrock R
PLoS One; 2011 Apr; 6(4):e18424. PubMed ID: 21494688
[TBL] [Abstract][Full Text] [Related]
27. G protein-coupled receptor kinases in normal and failing myocardium.
Huang ZM; Gold JI; Koch WJ
Front Biosci (Landmark Ed); 2011 Jun; 16(8):3047-60. PubMed ID: 21622221
[TBL] [Abstract][Full Text] [Related]
28. Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma.
Worrall C; Suleymanova N; Crudden C; Trocoli Drakensjö I; Candrea E; Nedelcu D; Takahashi SI; Girnita L; Girnita A
Oncogene; 2017 Jun; 36(23):3274-3286. PubMed ID: 28092675
[TBL] [Abstract][Full Text] [Related]
29. G-protein receptor kinases 2, 5 and 6 redundantly modulate Smoothened-GATA transcriptional crosstalk in fetal mouse hearts.
Franco A; Zhang L; Matkovich SJ; Kovacs A; Dorn GW
J Mol Cell Cardiol; 2018 Aug; 121():60-68. PubMed ID: 29969579
[TBL] [Abstract][Full Text] [Related]
30. Targeting the IGF1R/PI3K/AKT Pathway Sensitizes Ewing Sarcoma to BET Bromodomain Inhibitors.
Loganathan SN; Tang N; Holler AE; Wang N; Wang J
Mol Cancer Ther; 2019 May; 18(5):929-936. PubMed ID: 30926641
[TBL] [Abstract][Full Text] [Related]
31. GPCR kinases differentially modulate biased signaling downstream of CXCR3 depending on their subcellular localization.
Gardner J; Eiger DS; Hicks C; Choi I; Pham U; Chundi A; Namjoshi O; Rajagopal S
Sci Signal; 2024 Feb; 17(823):eadd9139. PubMed ID: 38349966
[TBL] [Abstract][Full Text] [Related]
32. Competing Engagement of β-arrestin Isoforms Balances IGF1R/p53 Signaling and Controls Melanoma Cell Chemotherapeutic Responsiveness.
Cismas S; Pasca S; Crudden C; Trocoli Drakensjo I; Suleymanova N; Zhang S; Gebhard B; Song D; Neo S; Shibano T; Smith TJ; Calin GA; Girnita A; Girnita L
Mol Cancer Res; 2023 Dec; 21(12):1288-1302. PubMed ID: 37584671
[TBL] [Abstract][Full Text] [Related]
33. GRK2-mediated receptor phosphorylation and Mdm2-mediated β-arrestin2 ubiquitination drive clathrin-mediated endocytosis of G protein-coupled receptors.
Zhang X; Zheng M; Kim KM
Biochem Biophys Res Commun; 2020 Dec; 533(3):383-390. PubMed ID: 32962859
[TBL] [Abstract][Full Text] [Related]
34. CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1-Dependent IGF-1 Signaling.
Sun H; Lin DC; Cao Q; Guo X; Marijon H; Zhao Z; Gery S; Xu L; Yang H; Pang B; Lee VK; Lim HJ; Doan N; Said JW; Chu P; Mayakonda A; Thomas T; Forscher C; Baloglu E; Shacham S; Rajalingam R; Koeffler HP
Cancer Res; 2016 May; 76(9):2687-97. PubMed ID: 26956669
[TBL] [Abstract][Full Text] [Related]
35. IGF1R signaling in Ewing sarcoma is shaped by clathrin-/caveolin-dependent endocytosis.
Martins AS; Ordóñez JL; Amaral AT; Prins F; Floris G; Debiec-Rychter M; Hogendoorn PC; de Alava E
PLoS One; 2011; 6(5):e19846. PubMed ID: 21611203
[TBL] [Abstract][Full Text] [Related]
36. GRK2 overexpression inhibits IGF1-induced proliferation and migration of human hepatocellular carcinoma cells by downregulating EGR1.
Ma Y; Han CC; Huang Q; Sun WY; Wei W
Oncol Rep; 2016 May; 35(5):3068-74. PubMed ID: 26936374
[TBL] [Abstract][Full Text] [Related]
37. Selective regulation of recombinantly expressed mGlu7 metabotropic glutamate receptors by G protein-coupled receptor kinases and arrestins.
Iacovelli L; Felicioni M; Nisticò R; Nicoletti F; De Blasi A
Neuropharmacology; 2014 Feb; 77():303-12. PubMed ID: 24148810
[TBL] [Abstract][Full Text] [Related]
38. Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents.
Amaral AT; Garofalo C; Frapolli R; Manara MC; Mancarella C; Uboldi S; Di Giandomenico S; Ordóñez JL; Sevillano V; Malaguarnera R; Picci P; Hassan AB; De Alava E; D'Incalci M; Scotlandi K
Clin Cancer Res; 2015 Mar; 21(6):1373-82. PubMed ID: 25609059
[TBL] [Abstract][Full Text] [Related]
39. An integrin binding-defective mutant of insulin-like growth factor-1 (R36E/R37E IGF1) acts as a dominant-negative antagonist of the IGF1 receptor (IGF1R) and suppresses tumorigenesis but still binds to IGF1R.
Fujita M; Ieguchi K; Cedano-Prieto DM; Fong A; Wilkerson C; Chen JQ; Wu M; Lo SH; Cheung AT; Wilson MD; Cardiff RD; Borowsky AD; Takada YK; Takada Y
J Biol Chem; 2013 Jul; 288(27):19593-603. PubMed ID: 23696648
[TBL] [Abstract][Full Text] [Related]
40. Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas.
Potratz JC; Saunders DN; Wai DH; Ng TL; McKinney SE; Carboni JM; Gottardis MM; Triche TJ; Jürgens H; Pollak MN; Aparicio SA; Sorensen PH
Cancer Res; 2010 Nov; 70(21):8770-81. PubMed ID: 20959493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
